Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Publication year range
1.
Transfus Med ; 27(4): 292-299, 2017 Aug.
Article in English | MEDLINE | ID: mdl-28524547

ABSTRACT

BACKGROUND AND OBJECTIVES: Cell salvage plays a key role in blood conservation. To maintain high performance, quality management is recommended. Accordingly, a new-generation autotransfusion device was tested for its performance and compared with its predecessor. Two different calculations of quality parameters were applied. MATERIALS AND METHODS: In an experimental study, the continuous autotransfusion devices CATSmart and Continuous Autotransfusion System (C.A.T.S) plus were tested using banked blood adjusted to a haematocrit of 20% and anticoagulated with heparin 5 U/L. Test blood was processed using an emergency programme, a high-quality programme/smart wash programme and a low-volume wash programme. Samples were taken after the production of 200 mL of red blood cells (RBC) and after the final emptying of the separation chamber. In an additional set of tests, blood containing 1·25% fat was processed with both devices to examine fat removal. RESULTS: Both devices demonstrated an equally high performance with regards to product hematocrit (Hct); RBC recovery; and elimination rates of protein, heparin and fat. The high fat elimination rate (>99·8%) reported for C.A.T.S plus was confirmed for CATSmart, regardless of the used programme. Samples taken during the ongoing process show a higher haematocrit and RBC recovery rate than samples taken after the final emptying of the separation chamber. Interface sensors were not affected by fat in the blood. CONCLUSIONS: The new-generation autotransfusion device CATSmart is not inferior to its predecessor and shows high performance with regards to RBC recovery, plasma and fat elimination in all programme modes. Samples for quality controls should be taken during blood processing.


Subject(s)
Blood Transfusion, Autologous/instrumentation , Erythrocytes , Lipids , Quality Control , Blood Transfusion, Autologous/methods , Hematocrit , Humans
2.
Anaesthesist ; 63(4): 313-25, 2014 Apr.
Article in German | MEDLINE | ID: mdl-24584840

ABSTRACT

The results of preclinical and clinical studies indicate that the perioperative period is a vulnerable period for cancer progression and metastasis. The risk of cancer cell dissemination is enhanced by the combination of surgical manipulation and perioperative immunosuppression. Whether the oncological outcome of cancer patients can be influenced by the choice of anesthetic techniques is still a matter of debate. This review summarizes the molecular characteristics of cancer and interaction of anesthetic and analgesic drugs with cancer cells.


Subject(s)
Analgesics/pharmacology , Anesthetics/pharmacology , Apoptosis/drug effects , Cell Line, Tumor , Neoplasms/pathology , Neovascularization, Pathologic/pathology , Animals , Humans , Immunosuppressive Agents/adverse effects , Neoplasms/blood supply , Neovascularization, Pathologic/prevention & control , Regional Blood Flow/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL
...